Urgent New Alert: About Coming Once-in-a-generation Wealth Shift
Here is the latest financial fact sheet of Natco Pharma. For more details, see the Natco Pharma quarterly results and Natco Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 1.5 |
No. of shares | m | 166.15 |
% ch week | % | 9.4 |
% ch 1-mth | % | 8.4 |
% ch 12-mth | % | 60.2 |
52 week H/L | Rs | 995.1/556.5 |
No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
---|
NATCO PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 2,291 | 624 | 849 | 1,080 | 849 | |
Low | Rs | 656 | 366 | 418 | 671 | 557 | |
Sales per share (Unadj.) | Rs | 248.4 | 327.8 | 578.9 | 592.1 | 573.8 | |
Earnings per share (Unadj.) | Rs | 37.6 | 43.5 | 138.9 | 188.4 | 176.0 | |
Diluted earnings per share | Rs | 7.5 | 9.1 | 29.2 | 41.8 | 38.7 | |
Cash flow per share (Unadj.) | Rs | 51.8 | 58.2 | 154.5 | 206.3 | 198.2 | |
Dividends per share (Unadj.) | Rs | 5.00 | 1.25 | 6.75 | 8.25 | 6.25 | |
Adj. dividends per share | Rs | 1.00 | 0.26 | 1.42 | 1.83 | 1.37 | |
Dividend yield (eoy) | % | 0.3 | 0.3 | 1.1 | 0.9 | 0.9 | |
Book value per share (Unadj.) | Rs | 254.6 | 372.8 | 473.8 | 833.6 | 842.7 | |
Adj. book value per share | Rs | 50.9 | 78.1 | 99.5 | 185.1 | 185.1 | |
Shares outstanding (eoy) | m | 33.23 | 34.83 | 34.90 | 36.90 | 36.50 | |
Bonus/Rights/Conversions | - | IS | IS | IS | BB | ||
Price / Sales ratio | x | 5.9 | 1.5 | 1.1 | 1.5 | 1.2 | |
Avg P/E ratio | x | 39.2 | 11.4 | 4.6 | 4.6 | 4.0 | |
P/CF ratio (eoy) | x | 28.4 | 8.5 | 4.1 | 4.2 | 3.5 | |
Price / Book Value ratio | x | 5.8 | 1.3 | 1.3 | 1.1 | 0.8 | |
Dividend payout | % | 13.3 | 2.9 | 4.9 | 4.4 | 3.6 | |
Avg Mkt Cap | Rs m | 48,963 | 17,230 | 22,116 | 32,311 | 25,660 | |
No. of employees | `000 | 3.1 | 1.3 | 4.4 | 4.8 | 5.0 | |
Total wages/salary | Rs m | 1,369 | 1,867 | 2,432 | 3,256 | 3,559 | |
Avg. sales/employee | Rs Th | 2,647.7 | 8,462.6 | 4,579.9 | 4,522.5 | 4,225.3 | |
Avg. wages/employee | Rs Th | 439.3 | 1,383.8 | 551.3 | 674.0 | 718.0 | |
Avg. net profit/employee | Rs Th | 400.8 | 1,124.2 | 1,099.3 | 1,439.0 | 1,295.9 |
NATCO PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 8,253 | 11,416 | 20,202 | 21,848 | 20,945 | |
Other income | Rs m | 149 | 108 | 139 | 404 | 1,302 | |
Total revenues | Rs m | 8,402 | 11,524 | 20,341 | 22,252 | 22,247 | |
Gross profit | Rs m | 2,100 | 2,640 | 6,834 | 9,284 | 7,948 | |
Depreciation | Rs m | 473 | 510 | 544 | 662 | 810 | |
Interest | Rs m | 317 | 229 | 185 | 154 | 193 | |
Profit before tax | Rs m | 1,459 | 2,009 | 6,244 | 8,872 | 8,247 | |
Minority Interest | Rs m | -44 | -14 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | -151 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 15 | 479 | 1,395 | 1,920 | 1,823 | |
Profit after tax | Rs m | 1,249 | 1,517 | 4,849 | 6,952 | 6,424 | |
Gross profit margin | % | 25.4 | 23.1 | 33.8 | 42.5 | 37.9 | |
Effective tax rate | % | 1.0 | 23.9 | 22.3 | 21.6 | 22.1 | |
Net profit margin | % | 15.1 | 13.3 | 24.0 | 31.8 | 30.7 |
NATCO PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 4,830 | 8,323 | 10,873 | 21,307 | 23,472 | |
Current liabilities | Rs m | 4,137 | 4,929 | 6,265 | 5,920 | 7,287 | |
Net working cap to sales | % | 8.4 | 29.7 | 22.8 | 70.4 | 77.3 | |
Current ratio | x | 1.2 | 1.7 | 1.7 | 3.6 | 3.2 | |
Inventory Days | Days | 97 | 114 | 63 | 73 | 92 | |
Debtors Days | Days | 85 | 84 | 86 | 107 | 88 | |
Net fixed assets | Rs m | 8,389 | 9,253 | 11,693 | 14,986 | 18,648 | |
Share capital | Rs m | 332 | 348 | 349 | 369 | 365 | |
"Free" reserves | Rs m | 7,945 | 12,373 | 16,144 | 30,353 | 34,525 | |
Net worth | Rs m | 8,461 | 12,983 | 16,534 | 30,760 | 30,760 | |
Long term debt | Rs m | 970 | 0 | 0 | 0 | 0 | |
Total assets | Rs m | 13,840 | 18,238 | 23,176 | 37,151 | 43,031 | |
Interest coverage | x | 5.6 | 9.8 | 34.8 | 58.6 | 43.7 | |
Debt to equity ratio | x | 0.1 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.6 | 0.6 | 0.9 | 0.6 | 0.5 | |
Return on assets | % | 11.3 | 9.6 | 21.7 | 19.1 | 15.4 | |
Return on equity | % | 14.8 | 11.7 | 29.3 | 22.6 | 20.9 | |
Return on capital | % | 16.8 | 17.1 | 38.9 | 29.3 | 27.4 | |
Exports to sales | % | 34.7 | 27.5 | 0 | 0 | 0 | |
Imports to sales | % | 6.5 | 10.2 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 2,866 | 3,141 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 538 | 1,168 | 0 | 0 | 0 | |
Fx inflow | Rs m | 3,156 | 3,457 | 6,793 | 10,322 | 11,536 | |
Fx outflow | Rs m | 959 | 1,688 | 2,254 | 2,978 | 2,939 | |
Net fx | Rs m | 2,197 | 1,769 | 4,538 | 7,343 | 8,597 |
NATCO PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 927 | 1,024 | 3,458 | 4,636 | 6,688 | |
From Investments | Rs m | -1,148 | -1,755 | -2,994 | -11,155 | -6,122 | |
From Financial Activity | Rs m | 291 | 856 | -477 | 6,509 | -509 | |
Net Cashflow | Rs m | 22 | 117 | -7 | -18 | 66 |
Share Holding
|
Company Information
|
CHM: V. C. Nannapaneni (MD) | COMP SEC: M. Adinarayana | YEAR OF INC: 1981 | BSE CODE: 524816 | FV (Rs): 10 | DIV YIELD (%): 0.1 |
More Pharmaceuticals Company Fact Sheets: CADILA HEALTHCARE AMAR REMEDIES TTK HEALTHCARE ELDER PHARMA ALKEM LABORATORIES
Compare NATCO PHARMA With: CADILA HEALTHCARE AMAR REMEDIES TTK HEALTHCARE ELDER PHARMA ALKEM LABORATORIES
Compare NATCO PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
More Views on NewsIn this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More